Interleukin 8, a Biomarker to Differentiate Guillain-Barré Syndrome From CIDP
Open Access
- 1 September 2021
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Neurology Neuroimmunology & Neuroinflammation
Abstract
Objective To determine whether CSF interleukin 8 (IL-8) concentration can help to distinguish Guillain-Barré syndrome (GBS) from chronic inflammatory demyelinating polyneuropathy (CIDP) at the initial stage of the disease. Methods We performed retrospective immunoassay of IL-8 in CSF, collected at the University Hospitals of Geneva between 2010 and 2018, from patients diagnosed with GBS (n = 45) and with CIDP (n = 30) according to the Brighton and European Federation of Neurological Societies/Peripheral Nerve Society criteria by a physician blinded to biological results. Results CSF IL-8 was higher in GBS (median: 83.9 pg/mL) than in CIDP (41.0 pg/mL) (p < 0.001). Receiver operating characteristic analyses indicated that the optimal IL-8 cutoff was 70 pg/mL. Above this value, patients were more likely to present GBS than CIDP (specificity 96.7%, sensitivity 64.4%, positive predictive value [PPV] 96.7%, and negative predictive value [NPV] 64.4%). Among GBS subcategories, IL-8 was higher in acute inflammatory demyelinating polyneuropathy (AIDP, median: 101.8 pg/mL) than in other GBS variants (median: 53.7 pg/mL). In addition, with CSF IL-8 above 70 pg/mL, patients were more likely to present AIDP than acute-onset CIDP (p < 0.001; specificity 100%, sensitivity 78.8%, PPV 100%, and NPV 46.2%) or other CIDP with nonacute presentation (p < 0.0001; specificity 95.8%, sensitivity 78.8%, PPV 96.3%, and NPV 76.7%). Conclusion CSF IL-8 levels can help to differentiate AIDP variant of GBS from CIDP, including acute-onset CIDP, with high specificity and PPV. This may improve early and appropriate treatment. Classification of Evidence This study provides Class II evidence that CSF IL-8 levels accurately distinguish patients with GBS from those with CIDP.Keywords
This publication has 9 references indexed in Scilit:
- IL-8 as a potential biomarker in Guillain-Barre SyndromeEuropean Cytokine Network, 2019
- Cerebrospinal fluid findings in Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathiesPublished by Elsevier BV ,2018
- Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory DiseasesTheranostics, 2017
- Diagnosis of Guillain-Barre syndrome and validation of Brighton criteriaBrain, 2013
- Guillain–Barré SyndromeThe New England Journal of Medicine, 2012
- Advances in the diagnosis, pathogenesis and treatment of CIDPNature Reviews Neurology, 2011
- The expression pattern of inflammatory mediators in cerebrospinal fluid differentiates Guillain–Barré syndrome from chronic inflammatory demyelinating polyneuropathyCytokine, 2010
- Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndromeNeurology, 2010
- European Federation of Neurological Societies/Peripheral Nerve Society Guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society — First RevisionEuropean Journal of Neurology, 2010